Jonathan A Pachter

8PUBLICATIONS
102CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 30, 2026
FAK inhibitor and RAF/MEK clamp avutometinib enhance KRAS G12C inhibitor efficacy in preclinical models of non-small cell lung cancer.

|Sep 29, 2026
Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition.

|Oct 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.

Xiuting Liu, John M Baer, Meredith L Stone

|Jun 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos

|Apr 18, 2023
Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.

Shih-Shih Chen, Jacqueline C Barrientos, Gerardo Ferrer

|Jan 27, 2022
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity.

Christopher Ronald Funk, Shuhua Wang, Kevin Z Chen

Pageof 2

Frequent Collaborators

3 joint publications

Silvia Coma

1 joint publications

Michael Andreeff

1 joint publications

Monica Acosta

1 joint publications

Robert Saddawi-Konefka